NCT05116345View on ClinicalTrials.gov

DEXTENZA for the Treatment of Pain and Inflammation Following Surgical Trabeculectomy and Ahmed Valve Procedures

PHASE4UnknownINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions

Glaucoma Following Surgery

Interventions

DRUG

DEXTENZA

Intracanalicular Dexamethasone ophthalmic insert (0.4mg)

DRUG

Topical Dexamethasone

topical dexamethasone drops

Trial Locations (1)

38103

Hamilton Eye Institute, Memphis

Sponsors

Collaborators (1)

Ocular Therapeutix, Inc.

All Listed Sponsors

collaborator

Ocular Therapeutix, Inc.

INDUSTRY

lead

Brian Jerkins, MD

OTHER

NCT05116345 - DEXTENZA for the Treatment of Pain and Inflammation Following Surgical Trabeculectomy and Ahmed Valve Procedures | Biotech Hunter | Biotech Hunter